University Hospital Virgen de las Nieves   Report issue

Academic/Hospital Phase 2 Phase 3 Phase 4
Founded: Granada Spain (1953)

Organization Overview

First Clinical Trial
2011
NCT01577368
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

University Hospital Virgen de las Nieves

Active Ingredients

Drugs in Phase 4 Trials (1)

human papillomavirus 9-valent vaccine, recombinant (Gardasil 9) (1 trial)

Drugs in Phase 3 Trials (2)

piperacillin (pipracil) (1 trial)

tazobactam (Zosyn) (1 trial)

Drugs in Phase 2 Trials (2)

axitinib (inlyta) (1 trial)

octreotide (sandostatin) (1 trial)

Drugs in Other Trials (1)

olive (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Communicable Diseases (Phase 4)

Infections (Phase 4)

Neuroendocrine Tumors (Phase 2)

Papillomavirus Infections (Phase 4)

Pseudomonas Infections (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 4
  • # of Trial APIs: 6